arrow
A

Alexis Ogdie

University of Pennsylvania
H指数:59
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Antimicrobial Use and Serious Infections Among Patients With Psoriatic Arthritis After Initiating Tumor Necrosis Factor Inhibitors: A Nationwide Matched Cohort Study (vol 52, pg 1098, 2025)

银屑病关节炎患者在使用肿瘤坏死因子抑制剂后抗菌药物使用与严重感染情况:一项全国性匹配队列研究(卷52,页1098,2025)

2026-02-010
PRE
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials

生物性别对参与者特征、Guselkumab疗效及影像学进展的影响:三项随机试验的回顾性分析

2025-12-150
OAAI
Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

托法替尼在银屑病关节炎患者中单药治疗与联合治疗的疗效:来自CorEvitas银屑病关节炎/脊柱关节炎登记研究的结果

2025-12-040
OA
Establishing Centers of Excellence for Psoriatic Disease in Latin America: Consensus Recommendations From the REAL-PANLAR Group

在拉丁美洲建立银屑病疾病卓越中心:REAL-PANLAR小组的共识建议

2025-12-010
PRE
Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials

利司那木单抗在生物制剂初治患者两项III期临床试验中,针对通过机器学习分析识别的不同银屑病关节炎表型的疗效

2025-11-290
OAAI
Antimicrobial Use and Serious Infections Among Patients With Psoriatic Arthritis After Initiating Tumor Necrosis Factor Inhibitors: A Nationwide Matched Cohort Study

银屑病关节炎患者应用肿瘤坏死因子抑制剂治疗后抗菌药物与严重感染的关系: 一项全国性匹配队列研究

2025-11-010
PRE
Construct Validity of the IDEOM Musculoskeletal Questionnaire: An Instrument to Measure Musculoskeletal Symptoms in Patients with Psoriatic Disease

IDEOM肌骨问卷的结构效度:用于测量银屑病疾病患者肌骨症状的工具

2025-01-270
PRE
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

bimekizumab治疗的活动性银屑病关节炎患者达到临床疾病控制标准与患者报告结局的关联: 两项III期研究的结果

2024-11-110
OAAI
Clinical Validation of Digitally Acquired Clinical Data and Machine Learning Models for Remote Measurement of Psoriasis and Psoriatic Arthritis: A Proof-of-Concept Study
2024-06-152
OA
DRUG SURVIVAL OF FIRST-LINE TNF AND APREMILAST AND DESCRIPTION OF SECOND- LINE THERAPY AMONG PSORIATIC ARTHRITIS (PSA) PATIENTS IN THE COREVITAS PSA/ SPONDYLOARTHRITIS (SPA) REGISTRY

银屑病关节炎(PSA)患者中,一线TNF和Apremilast的药物生存期及二线治疗情况的描述:基于COREVITAS PSA/脊柱关节炎(SPA)登记研究。

2024-06-010
PRE